Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor

NCT01260025 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01260025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01260025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2009
Completion date
January 31, 2011
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endostatin, pharmacokinetics, tolerability